Health Canada grants NOC for Biocon Biologics’ Yesintek and Yesintek I.V EP News Bureau Oct 23, 2025 Biocon Biologics receives Canadian approval for ustekinumab biosimilars for autoimmune conditions
Biocon Biologics, Yoshindo launch Ustekinumab biosimilar in Japan EP News Bureau May 21, 2025 Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA)
Biocon Biologics’ Ustekinumab Biosimilar receives positive CHMP opinion EP News Bureau Dec 16, 2024 YESINTEK recommended for approval to treat psoriasis, psoriatic arthritis, and Crohn’s disease in adults and children
